Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Okada M, Imagawa J, Tanaka H. et al.
DADI Trial Group, Japan. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment.

Clin Lymphoma Myeloma Leuk 2018;
18 (05) 353-360.e1

Bibliographische Angaben herunterladen

Aufrufen in: